Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dailyzar
- Development stage
- Phase 4
- Lead developer
- ADP Pharma Corporation
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dailyzar is an oral fixed-dose antihypertensive combination containing **losartan potassium 50 mg** and **amlodipine besilate 5 mg** per film-coated tablet. Losartan blocks angiotensin II type 1 receptors, reducing angiotensin II-mediated vasoconstriction and aldosterone signaling, while amlodipine is a dihydropyridine calcium-channel blocker that reduces calcium influx into vascular smooth muscle. ADP Pharma lists Dailyzar for the management of hypertension; the product is manufactured by Micro Labs. ([adppharma.com](https://www.adppharma.com/prescription-drugs/dailyzar/))
- Brand names
- Dailyzar
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on Dailyzar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dailyzar.